Loading viewer...
investor_presentation
Format: PDF investor_presentation
Madrigal Pharmaceuticals presents EASL investor event data on resmetirom (MGL-3196), an investigational therapy for non-alcoholic steatohepatitis (NASH). The presentation covers clinical trial results, development objectives, and potential efficacy for treating NASH and liver fibrosis.
investor_presentation
49 Pages
Sequana Medical